Illumina (ILMN) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
25 May, 2026Opening remarks and agenda
Meeting called to order at 10:00 A.M. with the CEO presiding as chairman.
Formal portion included voting on proposals, followed by a Q&A session.
Presence of management, board members, and independent accountants noted.
Corporate governance
Inspector of election appointed to examine and tabulate proxies and ballots.
List of registered stockholders available for inspection during the meeting.
Quorum established with majority of outstanding shares represented.
Overview of voting outcomes
Three items considered: election of nine directors, ratification of Ernst & Young as auditor, and advisory vote on executive compensation.
All director nominees received sufficient votes for election.
Ratification of Ernst & Young and approval of executive compensation both received sufficient votes.
Final certified tabulation to be filed with SEC within four business days.
Latest events from Illumina
- Q1 2026 revenue and margins rose, prompting higher guidance and a $1.5B share buyback.ILMN
Q1 20264 May 2026 - Q4 revenue up 5% to $1.16B, non-GAAP EPS up 42%, SomaLogic acquisition completed.ILMN
Q4 202520 Apr 2026 - Proxy seeks approval for director elections, auditor ratification, and executive pay, highlighting strong governance.ILMN
Proxy filing9 Apr 2026 - Virtual annual meeting to vote on directors, auditor, and executive pay, with board support.ILMN
Proxy filing9 Apr 2026 - Sequencing innovation, clinical growth, and end-to-end solutions drive strong outlook.ILMN
TD Cowen 46th Annual Health Care Conference3 Mar 2026 - Q2 revenue beat guidance, margins rose, but GRAIL impairments drove a $2.11B net loss.ILMN
Q2 20242 Feb 2026 - Targeting high single-digit revenue growth by 2027 through innovation and margin expansion.ILMN
Strategy Update2 Feb 2026 - MiSeq i100 Series delivers fast, sustainable, and user-friendly sequencing for diverse applications.ILMN
Status Update19 Jan 2026 - Q3 2024 saw strong margins and EPS, robust NovaSeq X adoption, and the GRAIL spin-off.ILMN
Q3 202416 Jan 2026